Who is sponsoring NCT03832582?

NCT03832582 is sponsored by Assistance Publique - Hôpitaux de Paris.

What drugs are being tested in NCT03832582?

Interventions in NCT03832582: Annexin.

What condition does NCT03832582 study?

NCT03832582 studies Chronic Dissection of Thoracic Aorta (Disorder).

Is NCT03832582 still recruiting?

NCT03832582 is currently status unknown. Last updated 11 February 2019.

Last reviewed 2019-02-11 · How we verify

NCT03832582: PAIDDA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Annexin Imaging in Dissection of the Descending Aorta

Status unknown Phase 2 Last updated 11 February 2019

What this trial tests

Phase 2 trial testing Annexin in Chronic Dissection of Thoracic Aorta (Disorder) in 83 participants. Status unknown.

Timeline

1 May 2019

Primary endpoint
31 May 2024

31 December 2024

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	83
Start date	1 May 2019
Primary completion	31 May 2024
Estimated completion	31 December 2024
Sites	1 location across France

Drugs / interventions tested

Annexin — full drug profile →

Conditions studied

Chronic Dissection of Thoracic Aorta (Disorder) — all drugs for Chronic Dissection of Thoracic Aorta (Disorder) →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

18 and older, any sex, with Chronic Dissection of Thoracic Aorta (Disorder). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The relationship between the presence of a partial thrombus and aortic dilation after type B dissection has recently been reported. The originality lies in the idea of imaging thrombus activity to predict dilation after type B dissection. The innovative character is based on the use of annexin scintigraphy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03832582 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
Last refreshed: 11 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03832582.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing